Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant CTLA-4 (Ipilimumab Biosimilar) antibody

Reactivity: Human FACS, in vivo Host: Mouse Monoclonal unconjugated Recombinant Antibody
Catalog No. ABIN7200671
  • Target See all CTLA-4 (Ipilimumab Biosimilar) products
    CTLA-4 (Ipilimumab Biosimilar)
    Antibody Type
    Recombinant Antibody
    Reactivity
    Human
    Host
    • 1
    • 1
    Mouse
    Clonality
    • 2
    Monoclonal
    Conjugate
    • 2
    This CTLA-4 (Ipilimumab Biosimilar) antibody is un-conjugated
    Application
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Purpose
    Ipilimumab Biosimilar, Human CTLA-4 Monoclonal Antibody
    Specificity
    The in vivo grade ipilimumab biosimilar specifically binds to the human CTLA4.
    Characteristics
    Recombinant fully human IgG1 monoclonal antibody.
    Purification
    Protein A affinity column
    Purity
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Sterility
    0.2 μm filtered
    Endotoxin Level
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogen
    The anti-human CTLA-4 monoclonal antibody ipilimumab biosimilar was produced in the ipilimumab biosimilar CHO stable cell line.
    Isotype
    IgG1 kappa
  • Application Notes
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ipilimumab.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Preservative
    Without preservative
    Handling Advice
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Storage
    -20 °C
    Storage Comment
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Expiry Date
    12 months
  • Target
    CTLA-4 (Ipilimumab Biosimilar)
    Abstract
    CTLA-4 (Ipilimumab Biosimilar) Products
    Synonyms
    CD antibody, CD152 antibody, CELIAC3 antibody, CTLA-4 antibody, GRD4 antibody, GSE antibody, IDDM12 antibody, cytotoxic T-lymphocyte associated protein 4 antibody, CTLA4 antibody
    Target Type
    Biosimilar
    Background
    What is Ipilimumab biosimilar research grade? Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.

    Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.

    Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.
You are here:
Support